BACKGROUND: Relative fat-free mass (FFM) deficiency (RFFMD) can also occur in obesity, but the impact on left ventricular (LV) mass is unknown. METHODS: We assessed relations among reduced FFM, obesity and LV mass in a population with high prevalence of obesity. Echocardiograms were performed in 2625 participants (1694 women, 1199 non-obese) of the Strong Heart Study cohort, free of prevalent cardiovascular disease and kidney failure. FFM was estimated by bioelectric impedance and analyzed in the non-obese subpopulation in relation with sex, BMI and waist-to-hip ratio (WHR). RFFMD was estimated in the obese subpopulation as the percent of observed/predicted FFM<20th percentile of the non-obese distribution. RESULTS: RFFMD was more frequent in women than men. LV mass indices (by either height(2.7) or FFM) were greater in obese with than in those without RFFMD, even after adjusting for sex and diabetes (both p<0.0001). The greater LV mass index in obesity with RFFMD was related mostly to increased LV diastolic dimension paralleling increased stroke index and cardiac index, in the presence of normal ejection fraction. RFFMD remained associated with greater LV mass index (p<0.0001) even independently of older age, greater BMI, higher systolic and lower diastolic blood pressure (all p<0.007), with negligible effect of sex, waist/hip ratio and diabetes. CONCLUSION: In obese SHS participants, RFFMD is associated with higher levels of LV mass, an effect related to adiposity more than central fat distribution and typical of female gender. Biological mechanisms of this association have to be better explored.
BACKGROUND: Relative fat-free mass (FFM) deficiency (RFFMD) can also occur in obesity, but the impact on left ventricular (LV) mass is unknown. METHODS: We assessed relations among reduced FFM, obesity and LV mass in a population with high prevalence of obesity. Echocardiograms were performed in 2625 participants (1694 women, 1199 non-obese) of the Strong Heart Study cohort, free of prevalent cardiovascular disease and kidney failure. FFM was estimated by bioelectric impedance and analyzed in the non-obese subpopulation in relation with sex, BMI and waist-to-hip ratio (WHR). RFFMD was estimated in the obese subpopulation as the percent of observed/predicted FFM<20th percentile of the non-obese distribution. RESULTS: RFFMD was more frequent in women than men. LV mass indices (by either height(2.7) or FFM) were greater in obese with than in those without RFFMD, even after adjusting for sex and diabetes (both p<0.0001). The greater LV mass index in obesity with RFFMD was related mostly to increased LV diastolic dimension paralleling increased stroke index and cardiac index, in the presence of normal ejection fraction. RFFMD remained associated with greater LV mass index (p<0.0001) even independently of older age, greater BMI, higher systolic and lower diastolic blood pressure (all p<0.007), with negligible effect of sex, waist/hip ratio and diabetes. CONCLUSION: In obese SHSparticipants, RFFMD is associated with higher levels of LV mass, an effect related to adiposity more than central fat distribution and typical of female gender. Biological mechanisms of this association have to be better explored.
Authors: R B Devereux; M J Roman; M Paranicas; M J O'Grady; E T Lee; T K Welty; R R Fabsitz; D Robbins; E R Rhoades; B V Howard Journal: Circulation Date: 2000-05-16 Impact factor: 29.690
Authors: Anne B Newman; Varant Kupelian; Marjolein Visser; Eleanor Simonsick; Bret Goodpaster; Michael Nevitt; Stephen B Kritchevsky; Frances A Tylavsky; Susan M Rubin; Tamara B Harris Journal: J Am Geriatr Soc Date: 2003-11 Impact factor: 5.562
Authors: Anne M Kenny; Latesha Dawson; Alison Kleppinger; Michele Iannuzzi-Sucich; James O Judge Journal: J Gerontol A Biol Sci Med Sci Date: 2003-05 Impact factor: 6.053
Authors: Giovanni de Simone; Paolo Verdecchia; Sergio Pede; Marco Gorini; Aldo Pietro Maggioni Journal: Hypertension Date: 2002-10 Impact factor: 10.190
Authors: S Ezzat; S Fear; R-C Gaillard; C Gayle; H Landy; S Marcovitz; T Mattioni; S Nussey; A Rees; E Svanberg Journal: J Clin Endocrinol Metab Date: 2002-06 Impact factor: 5.958
Authors: Giovanni de Simone; Richard B Devereux; Vittorio Palmieri; Jonathan N Bella; Albert Oberman; Dalane W Kitzman; Paul N Hopkins; D C Rao; Donna K Arnett Journal: J Hypertens Date: 2003-09 Impact factor: 4.844
Authors: L A Ferrara; B Capaldo; C Mancusi; E T Lee; B V Howard; R B Devereux; G de Simone Journal: Nutr Metab Cardiovasc Dis Date: 2013-10-09 Impact factor: 4.222
Authors: L A Ferrara; H Wang; J G Umans; N Franceschini; S Jolly; E T Lee; J Yeh; R B Devereux; B V Howard; G de Simone Journal: Nutr Metab Cardiovasc Dis Date: 2014-06-19 Impact factor: 4.222
Authors: S A Abbasi; W G Hundley; D A Bluemke; M Jerosch-Herold; R Blankstein; Steffen E Petersen; Oliver J Rider; J A C Lima; M A Allison; V L Murthy; R V Shah Journal: Nutr Metab Cardiovasc Dis Date: 2015-04-16 Impact factor: 4.222
Authors: Gernot Pichler; Maria Grau-Perez; Maria Tellez-Plaza; Jason Umans; Lyle Best; Shelley Cole; Walter Goessler; Kevin Francesconi; Jonathan Newman; Josep Redon; Richard Devereux; Ana Navas-Acien Journal: Circ Cardiovasc Imaging Date: 2019-05 Impact factor: 7.792
Authors: Giovanni de Simone; Costantino Mancusi; Roberta Esposito; Nicola De Luca; Maurizio Galderisi Journal: High Blood Press Cardiovasc Prev Date: 2018-05-02
Authors: Ben Corden; Antonio de Marvao; Timothy J Dawes; Wenzhe Shi; Daniel Rueckert; Stuart A Cook; Declan P O'Regan Journal: J Cardiovasc Magn Reson Date: 2016-05-31 Impact factor: 5.364